MedTrace Logo

Impact of a Communication Strategy in the Prevention of Depressive Symptoms in Patients with Covid-19

NCT05035563 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2025-01-13

No results posted yet for this study

Summary

The purpose of this study is to compare the effect of an early and integral communication strategy (EICS) versus standard care, on the rate of depressive symptoms at 3 months after discharge from the ICU, in patients with severe Covid-19, their family members and health personnel.

Evaluating the rate of depressive symptoms at 3 months after discharge from the ICU, with a) Hospital Anxiety and Depression, b) Posttraumatic Stress Disorder Checklist (S)

Conditions

  • Critical Illness
  • Mechanical Ventilation
  • Covid19

Interventions

BEHAVIORAL

Intervention. Early and integral communication strategy (EICS)

This intervention will be implemented in patients since they are hospitalized in the ICU where is expected: * Facilitate contact and communication between patients, families and the health team. * Respond to the communication needs of family members. * Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support. * Build a positive and trusting relationship of relatives and patients with health teams. The intervention considers the following actions: 1. \- Training in communication to the health team 2. \- Written material 3. \- Family website 4. \- Standardized and daily telephone information 5. \- Health Team Support Strategy 6. \- Weekly multidisciplinary virtual meeting with the family 7. \- ICU diaries for family members

Sponsors & Collaborators

  • University of Chile

    collaborator OTHER

  • Universidad de La Frontera

    collaborator OTHER

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Leyla Alegria · Pontificia Universidad Catolica de Chile

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-03-01
Completion
2022-07-01

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035563 on ClinicalTrials.gov